JP2019514373A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019514373A5 JP2019514373A5 JP2018555522A JP2018555522A JP2019514373A5 JP 2019514373 A5 JP2019514373 A5 JP 2019514373A5 JP 2018555522 A JP2018555522 A JP 2018555522A JP 2018555522 A JP2018555522 A JP 2018555522A JP 2019514373 A5 JP2019514373 A5 JP 2019514373A5
- Authority
- JP
- Japan
- Prior art keywords
- envelope glycoprotein
- retrovirus
- virus
- fusion protein
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims 41
- 230000008685 targeting Effects 0.000 claims 36
- 239000002245 particle Substances 0.000 claims 34
- 239000013598 vector Substances 0.000 claims 34
- 108020001507 fusion proteins Proteins 0.000 claims 33
- 102000037865 fusion proteins Human genes 0.000 claims 33
- 108090000623 proteins and genes Proteins 0.000 claims 32
- 241001430294 unidentified retrovirus Species 0.000 claims 30
- 102000004169 proteins and genes Human genes 0.000 claims 29
- 101710126503 Envelope glycoprotein G Proteins 0.000 claims 25
- 241000700605 Viruses Species 0.000 claims 23
- 241000711504 Paramyxoviridae Species 0.000 claims 18
- 241000035314 Henipavirus Species 0.000 claims 15
- 101710126504 Envelope glycoprotein H Proteins 0.000 claims 14
- 102100021696 Syncytin-1 Human genes 0.000 claims 14
- 108020004707 nucleic acids Proteins 0.000 claims 11
- 102000039446 nucleic acids Human genes 0.000 claims 11
- 150000007523 nucleic acids Chemical class 0.000 claims 11
- 101710121417 Envelope glycoprotein Proteins 0.000 claims 8
- 230000001086 cytosolic effect Effects 0.000 claims 8
- 102000003886 Glycoproteins Human genes 0.000 claims 7
- 108090000288 Glycoproteins Proteins 0.000 claims 7
- 108010046722 Thrombospondin 1 Proteins 0.000 claims 7
- 108010003533 Viral Envelope Proteins Proteins 0.000 claims 7
- 241000526636 Nipah henipavirus Species 0.000 claims 6
- 238000003776 cleavage reaction Methods 0.000 claims 6
- 230000007017 scission Effects 0.000 claims 6
- 150000001413 amino acids Chemical group 0.000 claims 5
- 238000000034 method Methods 0.000 claims 4
- 230000001177 retroviral effect Effects 0.000 claims 4
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 3
- 102000004127 Cytokines Human genes 0.000 claims 3
- 108090000695 Cytokines Proteins 0.000 claims 3
- 108700022150 Designed Ankyrin Repeat Proteins Proteins 0.000 claims 3
- 108010063738 Interleukins Proteins 0.000 claims 3
- 102000015696 Interleukins Human genes 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 3
- 230000004048 modification Effects 0.000 claims 3
- 238000012986 modification Methods 0.000 claims 3
- 230000035772 mutation Effects 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 102000005962 receptors Human genes 0.000 claims 3
- 108020003175 receptors Proteins 0.000 claims 3
- 230000002463 transducing effect Effects 0.000 claims 3
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 claims 2
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 claims 2
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims 2
- 241000893570 Hendra henipavirus Species 0.000 claims 2
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims 2
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 claims 2
- 101001018097 Homo sapiens L-selectin Proteins 0.000 claims 2
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims 2
- 101000926057 Human herpesvirus 2 (strain G) Envelope glycoprotein C Proteins 0.000 claims 2
- 102100022338 Integrin alpha-M Human genes 0.000 claims 2
- 108010002586 Interleukin-7 Proteins 0.000 claims 2
- 102100033467 L-selectin Human genes 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims 2
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 2
- 230000001640 apoptogenic effect Effects 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 210000004443 dendritic cell Anatomy 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 210000003494 hepatocyte Anatomy 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 210000000663 muscle cell Anatomy 0.000 claims 2
- 210000000653 nervous system Anatomy 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 210000002536 stromal cell Anatomy 0.000 claims 2
- 102000003390 tumor necrosis factor Human genes 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims 1
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims 1
- 101710132601 Capsid protein Proteins 0.000 claims 1
- 102000000844 Cell Surface Receptors Human genes 0.000 claims 1
- 108010001857 Cell Surface Receptors Proteins 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 102000018711 Facilitative Glucose Transport Proteins Human genes 0.000 claims 1
- 108091052347 Glucose transporter family Proteins 0.000 claims 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 1
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 claims 1
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 208000026350 Inborn Genetic disease Diseases 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- 108090000172 Interleukin-15 Proteins 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 108700011259 MicroRNAs Proteins 0.000 claims 1
- 241000712045 Morbillivirus Species 0.000 claims 1
- 208000021642 Muscular disease Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 108091027967 Small hairpin RNA Proteins 0.000 claims 1
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 210000000447 Th1 cell Anatomy 0.000 claims 1
- 210000004241 Th2 cell Anatomy 0.000 claims 1
- 102100036034 Thrombospondin-1 Human genes 0.000 claims 1
- 108010017070 Zinc Finger Nucleases Proteins 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- -1 antibody Proteins 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 210000001772 blood platelet Anatomy 0.000 claims 1
- 239000002771 cell marker Substances 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 238000001415 gene therapy Methods 0.000 claims 1
- 208000016361 genetic disease Diseases 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 230000011132 hemopoiesis Effects 0.000 claims 1
- 210000003630 histaminocyte Anatomy 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 229940079322 interferon Drugs 0.000 claims 1
- 108010074108 interleukin-21 Proteins 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 210000002540 macrophage Anatomy 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 239000002679 microRNA Substances 0.000 claims 1
- 210000001616 monocyte Anatomy 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 239000002858 neurotransmitter agent Substances 0.000 claims 1
- 210000000440 neutrophil Anatomy 0.000 claims 1
- 210000003924 normoblast Anatomy 0.000 claims 1
- 238000004806 packaging method and process Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 210000001948 pro-b lymphocyte Anatomy 0.000 claims 1
- 210000001978 pro-t lymphocyte Anatomy 0.000 claims 1
- 210000003289 regulatory T cell Anatomy 0.000 claims 1
- 239000004055 small Interfering RNA Substances 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000002255 vaccination Methods 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021148499A JP7577039B2 (ja) | 2016-04-21 | 2021-09-13 | 細胞の異なる亜型の活性を選択的にモジュレートするための方法 |
| JP2022064496A JP2022087199A (ja) | 2016-04-21 | 2022-04-08 | 細胞の異なる亜型の活性を選択的にモジュレートするための方法 |
| JP2024000186A JP7754959B2 (ja) | 2016-04-21 | 2024-01-04 | 細胞の異なる亜型の活性を選択的にモジュレートするための方法 |
| JP2025166535A JP2025188096A (ja) | 2016-04-21 | 2025-10-02 | 細胞の異なる亜型の活性を選択的にモジュレートするための方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16305468.7 | 2016-04-21 | ||
| EP16305468.7A EP3235908A1 (en) | 2016-04-21 | 2016-04-21 | Methods for selectively modulating the activity of distinct subtypes of cells |
| PCT/EP2017/059435 WO2017182585A1 (en) | 2016-04-21 | 2017-04-20 | Methods for selectively modulating the activity of distinct subtypes of cells |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021148499A Division JP7577039B2 (ja) | 2016-04-21 | 2021-09-13 | 細胞の異なる亜型の活性を選択的にモジュレートするための方法 |
| JP2022064496A Division JP2022087199A (ja) | 2016-04-21 | 2022-04-08 | 細胞の異なる亜型の活性を選択的にモジュレートするための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019514373A JP2019514373A (ja) | 2019-06-06 |
| JP2019514373A5 true JP2019514373A5 (https=) | 2020-06-11 |
| JP7412885B2 JP7412885B2 (ja) | 2024-01-15 |
Family
ID=56008561
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018555522A Active JP7412885B2 (ja) | 2016-04-21 | 2017-04-20 | 細胞の異なる亜型の活性を選択的にモジュレートするための方法 |
| JP2021148499A Active JP7577039B2 (ja) | 2016-04-21 | 2021-09-13 | 細胞の異なる亜型の活性を選択的にモジュレートするための方法 |
| JP2022064496A Pending JP2022087199A (ja) | 2016-04-21 | 2022-04-08 | 細胞の異なる亜型の活性を選択的にモジュレートするための方法 |
| JP2024000186A Active JP7754959B2 (ja) | 2016-04-21 | 2024-01-04 | 細胞の異なる亜型の活性を選択的にモジュレートするための方法 |
| JP2025166535A Pending JP2025188096A (ja) | 2016-04-21 | 2025-10-02 | 細胞の異なる亜型の活性を選択的にモジュレートするための方法 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021148499A Active JP7577039B2 (ja) | 2016-04-21 | 2021-09-13 | 細胞の異なる亜型の活性を選択的にモジュレートするための方法 |
| JP2022064496A Pending JP2022087199A (ja) | 2016-04-21 | 2022-04-08 | 細胞の異なる亜型の活性を選択的にモジュレートするための方法 |
| JP2024000186A Active JP7754959B2 (ja) | 2016-04-21 | 2024-01-04 | 細胞の異なる亜型の活性を選択的にモジュレートするための方法 |
| JP2025166535A Pending JP2025188096A (ja) | 2016-04-21 | 2025-10-02 | 細胞の異なる亜型の活性を選択的にモジュレートするための方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11608509B2 (https=) |
| EP (3) | EP3235908A1 (https=) |
| JP (5) | JP7412885B2 (https=) |
| KR (2) | KR20250035028A (https=) |
| CN (2) | CN117126817A (https=) |
| AU (4) | AU2017253364B2 (https=) |
| CA (1) | CA3021549A1 (https=) |
| EA (1) | EA201892369A1 (https=) |
| ES (1) | ES2961976T3 (https=) |
| IL (2) | IL262458B2 (https=) |
| MX (2) | MX2018012814A (https=) |
| SG (1) | SG11201809164TA (https=) |
| WO (1) | WO2017182585A1 (https=) |
| ZA (1) | ZA201807161B (https=) |
Families Citing this family (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9340799B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | MRNA-sensing switchable gRNAs |
| US11325948B2 (en) | 2016-03-19 | 2022-05-10 | Exuma Biotech Corp. | Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL |
| US12590321B2 (en) | 2016-03-19 | 2026-03-31 | Exuma Biotech Corp. | Methods and compositions for genetically modifying and expanding lymphocytes and regulating the activity thereof |
| US11111505B2 (en) | 2016-03-19 | 2021-09-07 | Exuma Biotech, Corp. | Methods and compositions for transducing lymphocytes and regulating the activity thereof |
| EP3235908A1 (en) | 2016-04-21 | 2017-10-25 | Ecole Normale Superieure De Lyon | Methods for selectively modulating the activity of distinct subtypes of cells |
| JP2020510038A (ja) | 2017-03-09 | 2020-04-02 | プレジデント アンド フェローズ オブ ハーバード カレッジ | がんワクチン |
| EP3592853A1 (en) | 2017-03-09 | 2020-01-15 | President and Fellows of Harvard College | Suppression of pain by gene editing |
| JP2020510439A (ja) | 2017-03-10 | 2020-04-09 | プレジデント アンド フェローズ オブ ハーバード カレッジ | シトシンからグアニンへの塩基編集因子 |
| AU2018266111B2 (en) | 2017-05-08 | 2024-11-07 | Flagship Pioneering Innovations V, Inc. | Compositions for facilitating membrane fusion and uses thereof |
| WO2019023680A1 (en) | 2017-07-28 | 2019-01-31 | President And Fellows Of Harvard College | METHODS AND COMPOSITIONS FOR EVOLUTION OF BASIC EDITORS USING PHAGE-ASSISTED CONTINUOUS EVOLUTION (PACE) |
| WO2019118949A1 (en) | 2017-12-15 | 2019-06-20 | The Broad Institute, Inc. | Systems and methods for predicting repair outcomes in genetic engineering |
| AU2019269593A1 (en) * | 2018-05-15 | 2020-11-26 | Flagship Pioneering Innovations V, Inc. | Fusosome compositions and uses thereof |
| US12522807B2 (en) | 2018-07-09 | 2026-01-13 | The Broad Institute, Inc. | RNA programmable epigenetic RNA modifiers and uses thereof |
| EP3820509A1 (en) | 2018-07-09 | 2021-05-19 | Flagship Pioneering Innovations V, Inc. | Fusosome compositions and uses thereof |
| US12496274B2 (en) | 2018-11-14 | 2025-12-16 | Flagship Pioneering Innovations V, Inc. | Compositions and methods for compartment-specific cargo delivery |
| WO2020102503A2 (en) * | 2018-11-14 | 2020-05-22 | Flagship Pioneering Innovations V, Inc. | Fusosome compositions for t cell delivery |
| SG11202105079QA (en) * | 2018-11-14 | 2021-06-29 | Flagship Pioneering Innovations V Inc | Fusosome compositions for cns delivery |
| EP3880832A1 (en) * | 2018-11-14 | 2021-09-22 | Flagship Pioneering Innovations V, Inc. | Fusosome compositions for hematopoietic stem cell delivery |
| US12351837B2 (en) | 2019-01-23 | 2025-07-08 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| JP7657726B2 (ja) | 2019-03-19 | 2025-04-07 | ザ ブロード インスティテュート，インコーポレーテッド | 編集ヌクレオチド配列を編集するための方法および組成物 |
| CN110004181B (zh) * | 2019-03-20 | 2022-10-11 | 东北农业大学 | 一种附加型CRISPR/Cas9表达载体及其构建方法与应用 |
| US12473543B2 (en) | 2019-04-17 | 2025-11-18 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| US12061187B2 (en) | 2019-05-23 | 2024-08-13 | Massachusetts Institute Of Technology | Ligand discovery and gene delivery via retroviral surface display |
| WO2020252455A1 (en) | 2019-06-13 | 2020-12-17 | The General Hospital Corporation | Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells |
| AU2020341454A1 (en) | 2019-09-03 | 2022-03-10 | Sana Biotechnology, Inc. | CD24-associated particles and related methods and uses thereof |
| KR20220108036A (ko) | 2019-09-26 | 2022-08-02 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 최소 아레스틴 도메인 함유 단백질 1 (arrdc1) 구축물 |
| CN110904116B (zh) * | 2019-10-24 | 2022-12-09 | 中国科学院遗传与发育生物学研究所 | 植物phl3基因在调控植物种子大小、干重和脂肪酸积累中的应用 |
| CA3171066A1 (en) | 2020-03-11 | 2021-09-16 | Saar GILL | Methods and composition for gene delivery using an engineered viral particle |
| JP2023521663A (ja) * | 2020-03-31 | 2023-05-25 | サナ バイオテクノロジー，インコーポレイテッド | 標的化脂質粒子及び組成物ならびにその使用 |
| EP4182447A4 (en) * | 2020-07-14 | 2024-10-23 | Ichilov Tech Ltd. | PSEUDOTYPED VIRUSES WITH CONFIGURATION FOR EXPRESSION OF CAR IN T CELLS |
| EP4185600A4 (en) | 2020-07-24 | 2024-12-04 | The General Hospital Corporation | Enhanced virus-like particles and methods of use thereof for delivery to cells |
| EP3964585A1 (en) * | 2020-09-03 | 2022-03-09 | Miltenyi Biotec B.V. & Co. KG | Cd62l specific lentiviral vector particle for targeted transduction of t cell subsets |
| EP4274901A1 (en) * | 2021-01-11 | 2023-11-15 | Sana Biotechnology, Inc. | Use of cd8-targeted viral vectors |
| AU2022227021A1 (en) | 2021-02-26 | 2023-09-21 | Kelonia Therapeutics, Inc. | Lymphocyte targeted lentiviral vectors |
| WO2022187289A1 (en) | 2021-03-01 | 2022-09-09 | Exuma Biotech Corp. | Methods and compositions for the delivery of retroviral particles |
| IL307544A (en) * | 2021-04-08 | 2023-12-01 | Sana Biotechnology Inc | Cd8-specific antibody constructs and compositions thereof |
| AU2022280957A1 (en) | 2021-05-28 | 2023-11-30 | Sana Biotechnology, Inc. | Lipid particles containing a truncated baboon endogenous retrovirus (baev) envelope glycoprotein and related methods and uses |
| WO2023015217A1 (en) | 2021-08-04 | 2023-02-09 | Sana Biotechnology, Inc. | Use of cd4-targeted viral vectors |
| US20250051797A1 (en) * | 2021-12-13 | 2025-02-13 | Interius Biotherapeutics, Inc. | Engineered viral particles and uses of the same |
| US20250059560A1 (en) | 2021-12-16 | 2025-02-20 | Sana Biotechnology, Inc. | Methods and systems of particle production |
| US20250059239A1 (en) | 2021-12-17 | 2025-02-20 | Sana Biotechnology, Inc. | Modified paramyxoviridae fusion glycoproteins |
| EP4448775A1 (en) | 2021-12-17 | 2024-10-23 | Sana Biotechnology, Inc. | Modified paramyxoviridae attachment glycoproteins |
| WO2023133595A2 (en) | 2022-01-10 | 2023-07-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| US20250144235A1 (en) | 2022-02-02 | 2025-05-08 | Sana Biotechnology, Inc. | Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses |
| US20250099612A1 (en) | 2022-03-01 | 2025-03-27 | Exuma Biotech Corp. | Viral particles with membrane-bound hyaluronidase |
| WO2023173140A2 (en) * | 2022-03-11 | 2023-09-14 | President And Fellows Of Harvard College | Targeted delivery of armms |
| US20250222027A1 (en) | 2022-04-01 | 2025-07-10 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
| US20250340899A1 (en) * | 2022-04-25 | 2025-11-06 | Tokiwa-Bio Inc. | Rna virus-derived chimeric envelope protein and rna virus vector having same |
| WO2024026377A1 (en) | 2022-07-27 | 2024-02-01 | Sana Biotechnology, Inc. | Methods of transduction using a viral vector and inhibitors of antiviral restriction factors |
| US20260055146A1 (en) | 2022-08-24 | 2026-02-26 | Sana Biotechnology, Inc. | Delivery of heterologous proteins |
| US20260098062A1 (en) | 2022-09-21 | 2026-04-09 | Sana Biotechnology, Inc. | Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof |
| WO2024081820A1 (en) | 2022-10-13 | 2024-04-18 | Sana Biotechnology, Inc. | Viral particles targeting hematopoietic stem cells |
| WO2024119157A1 (en) | 2022-12-02 | 2024-06-06 | Sana Biotechnology, Inc. | Lipid particles with cofusogens and methods of producing and using the same |
| EP4698665A1 (en) | 2023-04-18 | 2026-02-25 | Sana Biotechnology, Inc. | Engineered protein g fusogens and related lipid particles and methods thereof |
| WO2024220598A2 (en) | 2023-04-18 | 2024-10-24 | Sana Biotechnology, Inc. | Lentiviral vectors with two or more genomes |
| WO2024220597A2 (en) | 2023-04-18 | 2024-10-24 | Sana Biotechnology, Inc. | Digital droplet based assay for detecting replication competent lentiviral vector |
| EP4698666A1 (en) | 2023-04-18 | 2026-02-25 | Sana Biotechnology, Inc. | Universal protein g fusogens and adapter systems thereof and related lipid particles and uses |
| KR20260016952A (ko) | 2023-05-23 | 2026-02-04 | 사나 바이오테크놀로지, 인크. | 탠덤 퓨소젠 및 관련 지질 입자 |
| WO2024254346A1 (en) * | 2023-06-07 | 2024-12-12 | The Broad Institute, Inc. | Engineered viral like particles (evlps) for the selective transduction of target cells |
| CN116515865B (zh) * | 2023-06-19 | 2025-11-14 | 中国人民解放军军事科学院军事医学研究院 | 一种以人复制缺陷腺病毒为载体的尼帕病毒病疫苗 |
| AU2024353243A1 (en) | 2023-09-25 | 2026-04-09 | Kelonia Therapeutics, Inc. | Antigen binding polypeptides |
| AU2024353718A1 (en) | 2023-09-25 | 2026-04-09 | Kelonia Therapeutics, Inc. | Compositions for treating cancer |
| CN117659133B (zh) * | 2023-12-06 | 2024-09-20 | 南京鼓楼医院 | 间皮素靶向结合蛋白、其编码核酸以及用途 |
| WO2025176853A1 (en) * | 2024-02-22 | 2025-08-28 | Miltenyi Biotec B.V. & Co. KG | Cd4- or cd8-targeted retroviral vector particles for generation of cells expressing a bispecific chimeric antigen receptor |
| WO2025184529A1 (en) | 2024-03-01 | 2025-09-04 | Sana Biotechnology, Inc. | Viral particles with fusogen display and related compositions and methods |
| CN118108809B (zh) * | 2024-03-15 | 2025-02-28 | 西湖实验室(生命科学和生物医学浙江省实验室) | 一种跨膜荧光蛋白、水溶荧光蛋白及其用途 |
| WO2025252179A1 (zh) * | 2024-06-05 | 2025-12-11 | 深圳市济因生物科技有限公司 | 一种细胞外囊泡及其制备方法与应用 |
| KR102900650B1 (ko) * | 2024-08-01 | 2025-12-19 | 대한민국 | 니파바이러스 g 당단백질 유래 에피토프를 포함하는 펩타이드 및 이를 포함하는 백신 조성물 |
| CN120209100B (zh) * | 2025-03-28 | 2025-09-05 | 河北金要生物科技有限公司 | 一种表达mIL21和4-1BBL的病毒样颗粒及其在体外扩增NK细胞中的应用 |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ509978A (en) | 1998-09-23 | 2002-12-20 | Austrian Nordic Biotherapeutic | Removed particles protected against complement mediated destruction |
| US6896881B1 (en) * | 1999-09-24 | 2005-05-24 | Mayo Foundation For Medical Education And Research | Therapeutic methods and compositions using viruses of the recombinant paramyxoviridae family |
| WO2001074861A2 (en) | 2000-03-31 | 2001-10-11 | Mayo Foundation For Medical Education And Research | Compositions and methods for tissue specific gene regulation therapy |
| CA2464887A1 (en) | 2001-10-30 | 2003-05-08 | Biogen, Inc. | Methods and compositions for treating parkinson's disease |
| ES2627445T3 (es) | 2002-05-01 | 2017-07-28 | Miltenyi Biotec Technology, Inc. | Partículas de vector de lentivirus resistentes a la inactivación por el complemento |
| US20060045910A1 (en) | 2004-09-02 | 2006-03-02 | Ehringer William D | Preserved fusogenic vesicles |
| GB0426641D0 (en) | 2004-12-03 | 2005-01-05 | Bioactive Protein Delivery The | Protein delivery system |
| US8034331B2 (en) | 2005-01-20 | 2011-10-11 | Agency For Science, Technology And Research | Method of delivery of nucleic acids to peripheral neurons |
| PT1881845E (pt) | 2005-04-25 | 2010-05-31 | Merial Ltd | Vacinas de vírus nipah |
| WO2007005244A1 (en) | 2005-07-05 | 2007-01-11 | The Regents Of The University Of California | Henipavirus receptor and uses thereof |
| EP2062246A4 (en) | 2006-08-18 | 2010-09-29 | Univ North Carolina | VACCINES AGAINST CHIMARICAL VIRUSES |
| EP1975239A1 (en) * | 2006-09-27 | 2008-10-01 | Bundesrepublik Deutschland, letztvertreten durch den Präsidenten des Paul-Ehrlich-Instituts Prof. Dr. Johannes Löwer | Pseudotyping of retroviral vectors, methods for production and use thereof for targeted gene transfer and high-throughput screening |
| WO2008071959A1 (en) | 2006-12-12 | 2008-06-19 | Oxford Biomedica (Uk) Limited | Lentiviral vectors comprising micrornas |
| EP4154903A1 (en) | 2008-04-22 | 2023-03-29 | Vib Vzw | Liver-specific nucleic acid regulatory elements and methods and use thereof |
| CN102264349A (zh) | 2008-11-07 | 2011-11-30 | 儿童医院医疗中心 | 用于跨膜药物递送系统的鞘脂激活蛋白c以及相关蛋白和肽促融合性质 |
| ES2455544T5 (es) | 2009-07-24 | 2017-08-16 | Immune Design Corp | Vectores de lentivirus pseudotipificados con una glucoproteína de envoltura de virus sindbis |
| ES2693167T3 (es) | 2009-11-13 | 2018-12-07 | Inserm - Institut National De La Santé Et De La Recherche Médicale | Administración directa de proteínas con microvesículas modificadas por ingeniería |
| EP2476754A1 (en) | 2011-01-14 | 2012-07-18 | Bundesrepublik Deutschland, Letztvertreten Durch Den Präsidenten Des Paul-Ehrlich-Instituts | Methods for the identification and repair of amino acid residues destabilizing single-chain variable fragments (scFv) |
| AU2012249474A1 (en) | 2011-04-28 | 2013-11-07 | Stc.Unm | Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery and methods of using same |
| KR20200040899A (ko) * | 2011-05-13 | 2020-04-20 | 조에티스 서비시즈 엘엘씨 | 헨드라 및 니파 바이러스 ｇ 당단백질 면역원성 조성물 |
| JP2014532071A (ja) * | 2011-10-14 | 2014-12-04 | エスティーシー． ユーエヌエムＳｔｃ．Ｕｎｍ | カーゴの経皮送達を含む標的送達用の多孔性ナノ粒子に担持された脂質二重層（プロトセル）及びその方法 |
| GB201121070D0 (en) | 2011-12-07 | 2012-01-18 | Isis Innovation | composition for delivery of biotherapeutics |
| EP2615176A1 (en) * | 2012-01-11 | 2013-07-17 | Paul-Ehrlich-Institut Bundesamt für Sera und Impfstoffe | Novel pseudotyped lentiviral particles and their use in the in vitro targeted transduction of undifferentiated pluripotent human embryonic stem cells and induced pluripotent stem cells |
| WO2013148327A1 (en) | 2012-03-26 | 2013-10-03 | The Regents Of The University Of California | Nipah virus envelope psuedotyped lentiviruses and methods of their use |
| ES2686129T3 (es) | 2012-11-13 | 2018-10-16 | Codiak Biosciences, Inc. | Administración de agentes terapéuticos |
| CA2904969C (en) | 2013-03-13 | 2025-06-17 | Imaginab, Inc. | DIFFERENTIATION CLUSTER ANTIGEN-BINDING GENETIC CONSTRUCTIONS 8 |
| GB201313249D0 (en) | 2013-07-25 | 2013-09-11 | Isis Innovation | Method |
| EA037503B1 (ru) | 2014-01-21 | 2021-04-05 | Анджариум Байосайенсиз Аг | Способ получения гибридосомы, гибридосома, полученная при помощи способа, и способ доставки терапевтического или диагностического средства |
| GB201412494D0 (en) | 2014-07-14 | 2014-08-27 | Ospedale San Raffaele And Fond Telethon | Vector production |
| DK3256570T3 (da) * | 2015-02-11 | 2021-06-14 | Univ Bologna Alma Mater Studiorum | Retargeteret herpesvirus med en glycoprotein H-fusion |
| US10501733B2 (en) | 2015-02-27 | 2019-12-10 | University Of Washington | Polypeptide assemblies and methods for the production thereof |
| US20180135012A1 (en) | 2015-05-13 | 2018-05-17 | Rubius Therapeutics, Inc. | Membrane-receiver complex therapeutics |
| WO2017151717A1 (en) | 2016-03-01 | 2017-09-08 | French Brent A | Compositions and methods for adeno-associated virus mediated gene expression in myofibroblast-like cells |
| IL261713B2 (en) | 2016-03-19 | 2023-09-01 | F1 Oncology Inc | Methods and preparations for the transfer of lymphocytes and their regulated expansion |
| WO2017173034A1 (en) | 2016-03-30 | 2017-10-05 | The University Of North Carolina At Chapel Hill | Biological agent-exosome compositions and uses thereof |
| EP3235908A1 (en) | 2016-04-21 | 2017-10-25 | Ecole Normale Superieure De Lyon | Methods for selectively modulating the activity of distinct subtypes of cells |
| JP7072807B2 (ja) | 2016-06-09 | 2022-05-23 | アルマ・マテール・ストゥディオルム・ウニベルシータ・ディ・ボローニャ | 細胞内増殖のための改変糖タンパク質ｈを有するヘルペスウイルス |
| EP3472318B1 (en) | 2016-07-08 | 2023-09-06 | Exuma Biotech Corp. | Methods and compositions for transducing lymphocytes and regulating the activity thereof |
| KR20190053179A (ko) | 2016-07-26 | 2019-05-17 | 센티 바이오사이언시스, 인코포레이티드 | 유전자 지우개들 |
| AU2018206485B2 (en) | 2017-01-09 | 2024-12-05 | Oisin Biotechnologies | Fusogenic lipid nanoparticles and methods for manufacturing and use for therapeutic protein production and for treatment |
| AU2018266111B2 (en) | 2017-05-08 | 2024-11-07 | Flagship Pioneering Innovations V, Inc. | Compositions for facilitating membrane fusion and uses thereof |
| US20210187018A1 (en) | 2017-12-07 | 2021-06-24 | Flagship Pioneering Innovations V, Inc. | Cytobiologics and therapeutic uses thereof |
| AU2019215063B2 (en) | 2018-02-01 | 2025-10-16 | Bioverativ Therapeutics, Inc. | Use of lentiviral vectors expressing Factor VIII |
| CA3091478A1 (en) | 2018-02-17 | 2019-08-22 | Flagship Pioneering Innovations V, Inc. | Compositions and methods for membrane protein delivery |
| AU2019269593A1 (en) | 2018-05-15 | 2020-11-26 | Flagship Pioneering Innovations V, Inc. | Fusosome compositions and uses thereof |
| EP3820509A1 (en) | 2018-07-09 | 2021-05-19 | Flagship Pioneering Innovations V, Inc. | Fusosome compositions and uses thereof |
| EP3880832A1 (en) | 2018-11-14 | 2021-09-22 | Flagship Pioneering Innovations V, Inc. | Fusosome compositions for hematopoietic stem cell delivery |
| SG11202105079QA (en) | 2018-11-14 | 2021-06-29 | Flagship Pioneering Innovations V Inc | Fusosome compositions for cns delivery |
| US12496274B2 (en) | 2018-11-14 | 2025-12-16 | Flagship Pioneering Innovations V, Inc. | Compositions and methods for compartment-specific cargo delivery |
| WO2020102503A2 (en) | 2018-11-14 | 2020-05-22 | Flagship Pioneering Innovations V, Inc. | Fusosome compositions for t cell delivery |
-
2016
- 2016-04-21 EP EP16305468.7A patent/EP3235908A1/en not_active Withdrawn
-
2017
- 2017-04-20 IL IL262458A patent/IL262458B2/en unknown
- 2017-04-20 EA EA201892369A patent/EA201892369A1/ru unknown
- 2017-04-20 KR KR1020257006420A patent/KR20250035028A/ko active Pending
- 2017-04-20 EP EP17720053.2A patent/EP3445862B1/en active Active
- 2017-04-20 CA CA3021549A patent/CA3021549A1/en active Pending
- 2017-04-20 KR KR1020187033628A patent/KR102775926B1/ko active Active
- 2017-04-20 US US16/094,636 patent/US11608509B2/en active Active
- 2017-04-20 EP EP22194343.4A patent/EP4151737A1/en active Pending
- 2017-04-20 WO PCT/EP2017/059435 patent/WO2017182585A1/en not_active Ceased
- 2017-04-20 SG SG11201809164TA patent/SG11201809164TA/en unknown
- 2017-04-20 JP JP2018555522A patent/JP7412885B2/ja active Active
- 2017-04-20 CN CN202311091685.0A patent/CN117126817A/zh active Pending
- 2017-04-20 AU AU2017253364A patent/AU2017253364B2/en active Active
- 2017-04-20 MX MX2018012814A patent/MX2018012814A/es unknown
- 2017-04-20 ES ES17720053T patent/ES2961976T3/es active Active
- 2017-04-20 CN CN201780039032.4A patent/CN109642243A/zh active Pending
-
2018
- 2018-10-19 MX MX2023006961A patent/MX2023006961A/es unknown
- 2018-10-26 ZA ZA2018/07161A patent/ZA201807161B/en unknown
-
2020
- 2020-06-10 AU AU2020203813A patent/AU2020203813B2/en active Active
-
2021
- 2021-09-13 JP JP2021148499A patent/JP7577039B2/ja active Active
-
2022
- 2022-04-08 JP JP2022064496A patent/JP2022087199A/ja active Pending
-
2023
- 2023-03-06 US US18/179,269 patent/US20230348934A1/en active Pending
- 2023-10-31 AU AU2023258359A patent/AU2023258359B2/en active Active
-
2024
- 2024-01-04 JP JP2024000186A patent/JP7754959B2/ja active Active
-
2025
- 2025-06-19 IL IL321626A patent/IL321626A/en unknown
- 2025-10-02 JP JP2025166535A patent/JP2025188096A/ja active Pending
-
2026
- 2026-03-18 AU AU2026202115A patent/AU2026202115A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019514373A5 (https=) | ||
| US20260048139A1 (en) | Therapeutic agents comprising nucleic acids and car-modified immune cells, and uses thereof | |
| JP2022087199A (ja) | 細胞の異なる亜型の活性を選択的にモジュレートするための方法 | |
| JP6612963B2 (ja) | 腫瘍抗原を直接認識するために組換えｔ細胞レセプターを使用するための組成物及び方法 | |
| JP6971986B2 (ja) | 免疫療法の抗腫瘍活性を高めるための間葉系幹細胞 | |
| CN111743923B (zh) | 包含分离的重组溶瘤腺病毒和免疫细胞的治疗剂及其应用 | |
| JPWO2010030002A1 (ja) | 外来性ｇｉｔｒリガンド発現細胞 | |
| WO2019096115A1 (zh) | 分离的t细胞受体、其修饰的细胞、编码核酸、表达载体、制备方法、药物组合物和应用 | |
| CA3129229A1 (en) | Chimeric cytokine receptors | |
| US20250144211A1 (en) | Recombinant proteins that stimulate an immune response in the presence of naturally inhibitory ligand binding | |
| US20240066127A1 (en) | Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof | |
| CN111499766B (zh) | 针对慢性淋巴细胞白血病的免疫效应细胞、其制备方法和应用 | |
| CN118108856A (zh) | 靶向cd5分子的嵌合抗原受体nk细胞及其抗肿瘤应用 | |
| CN116254230A (zh) | 用于制备和扩增通用型人源化抗cd19 car-nk细胞的方法及其用途 | |
| JP2023545413A (ja) | Ｔ細胞受容体、ｔ細胞受容体を含む免疫細胞およびそれを用いる方法｛ｔ ｃｅｌｌ ｒｅｃｅｐｔｏｒｓ、ｉｍｍｕｎｅ ｃｅｌｌ ｃｏｍｐｒｉｓｉｎｇ ｔ ｃｅｌｌ ｒｅｃｅｐｔｏｒｓ ａｎｄ ｍｅｔｈｏｄ ｕｓｉｎｇ ｔｈｅ ｓａｍｅ｝ | |
| WO2017139199A1 (en) | Inducible arginase | |
| US20260028388A1 (en) | Recombinant cytokine receptors and methods of use | |
| US20250333697A1 (en) | Tethered interleukin-2 recombinant receptors and methods of use | |
| US20230212257A1 (en) | Anti-cd171 chimeric antigen receptors | |
| CN121969642A (zh) | 一种增强型嵌合人cd8共受体、编码该增强型嵌合人cd8共受体的核酸、相应的载体、用所述核酸或相应的载体转导的分离的t细胞和用于制备其的试剂盒，以及相应的药物组合物和用于治疗患有疾病的患者的方法 | |
| WO2025007073A2 (en) | Synthetic cytokine receptors | |
| WO2025034618A1 (en) | A novel t-cell receptor and uses thereof | |
| CN119039461A (zh) | 一种新型嵌合受体及其应用 | |
| HK40086476B (zh) | 嵌合转换受体基因修饰的nk细胞制备方法及应用 | |
| HK40086476A (zh) | 嵌合转换受体基因修饰的nk细胞制备方法及应用 |